

EBOS GROUP LIMITED

INTERIM REPORT
FOR THE SIX MONTHS
ENDED 31 DECEMBER 2024

CONTENTS	Page
Summary of Consolidated Financial Highlights	1
Shareholder Calendar	1
Auditor's Independent Review Report	2
Condensed Consolidated Income Statement	3
Condensed Consolidated Statement of Comprehensive Income	4
Condensed Consolidated Statement of Changes in Equity	5
Condensed Consolidated Balance Sheet	8
Condensed Consolidated Cash Flow Statement	9
Notes to the Condensed Consolidated Interim Financial Statements	10
Directory	19

EBOS GROUP LIMITED
INTERIM REPORT 2025
SUMMARY OF CONSOLIDATED FINANCIAL HIGHLIGHTS

	Six months 31 Dec 24 A\$'000 (unaudited)	Six months 31 Dec 23 A\$'000 (unaudited)	Year ended 30 Jun 24 A\$'000 (audited)
Revenue	5,991,410	6,582,488	13,189,054
Earnings before depreciation, amortisation, net finance costs and tax expense (EBITDA)	275,838	303,067	605,595
Earnings before net finance costs and tax expense (EBIT)	207,276	236,724	476,724
Profit before tax expense	155,846	191,958	383,103
Profit for the period	111,719	137,256	273,085
Profit for the period attributable to owners of the Company	110,489	136,175	271,549
Equity attributable to owners of the Company	2,481,123	2,365,227	2,451,009
Earnings per share	56.9c	71.0c	141.3c
Interim dividend per share (New Zealand dollars)	57.0c	57.0c	57.0c

SHAREHOLDER CALENDAR

Interim dividend record date	28 February 2025
Interim dividend payable	21 March 2025
Release of 2025 full year results	20 August 2025
Annual Meeting	29 October 2025

INDEPENDENT AUDITOR'S REVIEW REPORT TO THE SHAREHOLDERS OF EBOS GROUP LIMITED

Conclusion

We have reviewed the condensed consolidated interim financial statements ('interim financial statements') of EBOS Group Limited and its subsidiaries ('the Group') on pages 3 to 18 which comprise the condensed consolidated balance sheet as at 31 December 2024, and the condensed consolidated income statement, condensed consolidated statement of comprehensive income, condensed consolidated statement of changes in equity and condensed consolidated cash flow statement for the six months ended on that date, and notes to the interim financial statements, including material accounting policy information.

Based on our review, nothing has come to our attention that causes us to believe that the interim financial statements of the Group do not present fairly, in all material respects, the financial position of the Group as at 31 December 2024 and its financial performance and cash flows for the six month ended on that date in accordance with NZ IAS 34 *Interim Financial Reporting* and IAS 34 *Interim Financial Reporting*.

Basis for Conclusion

We conducted our review in accordance with NZ SRE 2410 (Revised) *Review of Financial Statements Performed by the Independent Auditor of the Entity* ('NZ SRE 2410 (Revised)'). Our responsibilities are further described in the *Auditor's Responsibilities for the Review of the Interim Financial Statements* section of our report.

We are independent of the Group in accordance with the relevant ethical requirements in New Zealand relating to the audit of the annual financial statements, and we have fulfilled our other ethical responsibilities in accordance with these requirements.

Our firm carries out other assignments for the Group in the area of other assurance services. These services have not impaired our independence as auditor of the Company. In addition to this, partners and employees of our firm deal with the Group on normal terms within the ordinary course of trading activities of the business of the Group. The firm has no other relationship with, or interest in, the Group.

Directors' responsibilities for the interim financial statements

The directors are responsible on behalf of the Group for the preparation and fair presentation of the interim financial statements in accordance with NZ IAS 34 *Interim Financial Reporting* and IAS 34 *Interim Financial Reporting* and for such internal control as the directors determine is necessary to enable the preparation and fair presentation of the interim financial statements that are free from material misstatement, whether due to fraud or error.

Auditor's responsibilities for the review of the interim financial statements

Our responsibility is to express a conclusion on the interim financial statements based on our review. NZ SRE 2410 (Revised) requires us to conclude whether anything has come to our attention that causes us to believe that the interim financial statements, taken as a whole, are not prepared, in all material respects, in accordance with NZ IAS 34 *Interim Financial Reporting* and IAS 34 *Interim Financial Reporting*.

A review of the interim financial statements in accordance with NZ SRE 2410 (Revised) is a limited assurance engagement. We perform procedures, primarily consisting of making enquiries, primarily of persons responsible for financial and accounting matters, and applying analytical and other review procedures. The procedures performed in a review are substantially less than those performed in an audit conducted in accordance with International Standards on Auditing (New Zealand) and consequently do not enable us to obtain assurance that we would become aware of all significant matters that might be identified in an audit. Accordingly we do not express an audit opinion on the interim financial statements.

Restriction on use

This report is made solely to the company's shareholders, as a body. Our review has been undertaken so that we might state to the company's shareholders those matters we are required to state to them in a review report and for no other purpose. To the fullest extent permitted by law, we do not accept or assume responsibility to anyone other than the company's shareholders as a body, for our engagement, for this report, or for the conclusions we have formed.

Deloitte Limited

Mike Hoshek, Partner
for Deloitte Limited
Christchurch, New Zealand
18 February 2025

EBOS GROUP LIMITED
CONDENSED CONSOLIDATED INCOME STATEMENT

For the six months ended 31 December 2024

	Notes	Six months 31 Dec 24 A\$'000 (unaudited)	Six months 31 Dec 23 A\$'000 (unaudited)	Year ended 30 Jun 24 A\$'000 (audited)
Revenue	2(a)	5,991,410	6,582,488	13,189,054
Income from associates		7,807	6,534	12,938
Earnings before depreciation, amortisation, net finance costs and tax expense (EBITDA)		275,838	303,067	605,595
Depreciation	2(b)	(47,336)	(48,050)	(92,459)
Amortisation	2(b)	(21,226)	(18,293)	(36,412)
Earnings before net finance costs and tax expense (EBIT)		207,276	236,724	476,724
Finance income		3,552	3,952	7,320
Finance costs – borrowings		(44,107)	(41,118)	(83,290)
Finance costs – leases		(10,875)	(7,600)	(17,651)
Profit before tax expense		155,846	191,958	383,103
Income tax expense		(44,127)	(54,702)	(110,018)
Profit for the period		111,719	137,256	273,085
Profit for the period attributable to:				
Owners of the Company		110,489	136,175	271,549
Non-controlling interests		1,230	1,081	1,536
		111,719	137,256	273,085
Earnings per share				
Basic (cents per share)		56.9	71.0	141.3
Diluted (cents per share)		56.9	71.0	141.3

Notes to the financial statements are included on pages 10 to 18.

EBOS GROUP LIMITED**CONDENSED CONSOLIDATED STATEMENT OF COMPREHENSIVE INCOME**

For the six months ended 31 December 2024

	Six months 31 Dec 24 A\$'000 (unaudited)	Six months 31 Dec 23 A\$'000 (unaudited)	Year ended 30 Jun 24 A\$'000 (audited)
Profit for the period	111,719	137,256	273,085
Other comprehensive income			
Items that may be reclassified subsequently to profit or loss:			
Movement in cash flow hedge reserve	1,365	(10,628)	(6,726)
Related income tax	(410)	3,300	1,907
Movement in foreign currency translation reserve	5,434	1,398	(7,061)
	6,389	(5,930)	(11,880)
Items that will not be reclassified subsequently to profit or loss:			
Movement on equity instruments fair valued through other comprehensive income	(16,160)	(938)	5,801
Total comprehensive income net of tax	101,948	130,388	267,006
Total comprehensive income for the period is attributable to:			
Owners of the Company	99,788	129,449	265,716
Non-controlling interests	2,160	939	1,290
	101,948	130,388	267,006

Notes to the financial statements are included on pages 10 to 18.

EBOS GROUP LIMITED
CONDENSED CONSOLIDATED STATEMENT OF CHANGES IN EQUITY

For the six months ended 31 December 2024

	Notes	Share capital A\$'000	Share based payments reserve A\$'000	Foreign currency translation reserve A\$'000	Retained earnings A\$'000	Equity instruments fair valued through other comprehensive income reserve A\$'000	Cash flow hedge reserve A\$'000	Non-controlling interests A\$'000	Total A\$'000
Six months ended 31 December 2023 (unaudited):									
Opening balance		1,889,863	16,210	(31,311)	559,428	(4,986)	5,188	(131,032)	2,303,360
Profit for the period		-	-	-	136,175	-	-	1,081	137,256
Other comprehensive income for the period, net of tax		-	-	1,540	-	(938)	(7,328)	(142)	(6,868)
Payment of dividends	4	-	-	-	(100,879)	-	-	-	(100,879)
Movement in option over non-controlling interests		-	-	-	-	-	-	(2,626)	(2,626)
Transfer of non-controlling interests		-	-	-	32,768	-	-	(32,768)	-
Partial derecognition of option over non-controlling interests		-	-	-	(134,626)	-	-	134,626	-
Share-based payments		-	3,265	-	-	-	-	-	3,265
Employee share plan shares issued	3	932	-	-	-	-	-	-	932
Employee share issue costs	3	(74)	-	-	-	-	-	-	(74)
Balance at 31 December 2023		1,890,721	19,475	(29,771)	492,866	(5,924)	(2,140)	(30,861)	2,334,366

Notes to the financial statements are included on pages 10 to 18.

EBOS GROUP LIMITED
CONDENSED CONSOLIDATED STATEMENT OF CHANGES IN EQUITY (Continued)

For the six months ended 31 December 2024

	Notes	Share capital A\$'000	Share based payments reserve A\$'000	Foreign currency translation reserve A\$'000	Retained earnings A\$'000	Equity instruments fair valued through other comprehensive income reserve A\$'000	Cash flow hedge reserve A\$'000	Non-controlling interests A\$'000	Total A\$'000
Year ended 30 June 2024 (audited):									
Opening balance		1,889,863	16,210	(31,311)	559,428	(4,986)	5,188	(131,032)	2,303,360
Profit for the period		-	-	-	271,549	-	-	1,536	273,085
Other comprehensive income for the period, net of tax		-	-	(6,815)	-	5,801	(4,819)	(246)	(6,079)
Payment of dividends	4	-	-	-	(203,675)	-	-	-	(203,675)
Movement in option over non-controlling interests		-	-	-	-	-	-	(4,626)	(4,626)
Transfer of non-controlling interests		-	-	-	32,768	-	-	(32,768)	-
Partial derecognition of option over non-controlling interests		-	-	-	(134,626)	-	-	134,626	-
Share-based payments		-	9,087	-	-	-	-	-	9,087
Dividends reinvested	3	45,736	-	-	-	-	-	-	45,736
Employee share plan shares issued	3	1,808	-	-	-	-	-	-	1,808
Employee share issue costs	3	(197)	-	-	-	-	-	-	(197)
Balance at 30 June 2024		1,937,210	25,297	(38,126)	525,444	815	369	(32,510)	2,418,499

Notes to the financial statements are included on pages 10 to 18.

EBOS GROUP LIMITED
CONDENSED CONSOLIDATED STATEMENT OF CHANGES IN EQUITY (Continued)

For the six months ended 31 December 2024

	Notes	Share capital A\$'000	Share based payments reserve A\$'000	Foreign currency translation reserve A\$'000	Retained earnings A\$'000	Equity instruments fair valued through other comprehensive income reserve A\$'000	Cash flow hedge reserve A\$'000	Non-controlling interests A\$'000	Total A\$'000
Six months ended 31 December 2024 (unaudited):									
Opening balance		1,937,210	25,297	(38,126)	525,444	815	369	(32,510)	2,418,499
Profit for the period		-	-	-	110,489	-	-	1,230	111,719
Other comprehensive income for the period, net of tax		-	-	4,504	-	(16,160)	955	930	(9,771)
Payment of dividends	4	-	-	-	(108,167)	-	-	-	(108,167)
Movement in option over non-controlling interests		-	-	-	-	-	-	(11,000)	(11,000)
Transfer to retained earnings		-	-	-	(1,285)	1,285	-	-	-
Share-based payments		-	(1,013)	-	-	-	-	-	(1,013)
Dividends reinvested	3	38,663	-	-	-	-	-	-	38,663
Employee share plan shares issued	3	959	-	-	-	-	-	-	959
Employee share issue costs	3	(116)	-	-	-	-	-	-	(116)
Balance at 31 December 2024		1,976,716	24,284	(33,622)	526,481	(14,060)	1,324	(41,350)	2,439,773

Notes to the financial statements are included on pages 10 to 18.

EBOS GROUP LIMITED
CONDENSED CONSOLIDATED BALANCE SHEET

As at 31 December 2024

	Notes	31 Dec 2024 A\$'000 (unaudited)	31 Dec 2023 A\$'000 (unaudited)	30 June 2024 A\$'000 (audited)
Current assets				
Cash and cash equivalents		237,928	365,313	216,883
Trade and other receivables		1,423,712	1,527,086	1,494,564
Prepayments		46,108	51,394	48,756
Inventories		1,246,436	1,334,278	1,210,440
Current tax refundable		8,245	3,509	4,822
Other financial assets – derivatives	8	5,924	4,701	6,727
Total current assets		2,968,353	3,286,281	2,982,192
Non-current assets				
Property, plant and equipment		399,718	343,514	383,909
Capital work in progress		72,389	81,534	61,563
Prepayments		5,797	267	1,553
Deferred tax assets		235,117	225,564	238,927
Goodwill	9	2,126,765	2,041,543	2,067,694
Indefinite life intangibles		191,924	193,460	192,481
Finite life intangibles		358,908	331,233	337,426
Right of use assets		387,052	356,447	388,952
Investment in associates		60,511	51,905	56,440
Other financial assets		36,794	23,972	32,925
Total non-current assets		3,874,975	3,649,439	3,761,870
Total assets		6,843,328	6,935,720	6,744,062
Current liabilities				
Trade and other payables		2,209,333	2,340,387	2,212,533
Bank loans	7	47,592	171,729	765,708
Lease liabilities		58,133	55,830	57,239
Current tax payable		14,242	14,213	6,451
Employee benefits		66,185	70,259	81,848
Other financial liabilities – derivatives	8	46,449	493	617
Total current liabilities		2,441,934	2,652,911	3,124,396
Non-current liabilities				
Bank loans	7	1,255,000	1,281,823	470,102
Lease liabilities		350,066	325,897	349,914
Trade and other payables		51,580	20,164	36,921
Deferred tax liabilities		294,058	278,343	298,741
Employee benefits		10,917	9,216	10,489
Other financial liabilities – derivatives	8	-	33,000	35,000
Total non-current liabilities		1,961,621	1,948,443	1,201,167
Total liabilities		4,403,555	4,601,354	4,325,563
Net assets		2,439,773	2,334,366	2,418,499
Equity				
Share capital	3	1,976,716	1,890,721	1,937,210
Share based payments reserve		24,284	19,475	25,297
Foreign currency translation reserve		(33,622)	(29,771)	(38,126)
Retained earnings		526,481	492,866	525,444
Equity instruments fair valued through other comprehensive income		(14,060)	(5,924)	815
Cash flow hedge reserve		1,324	(2,140)	369
Equity attributable to owners of the company		2,481,123	2,365,227	2,451,009
Non-controlling interests		(41,350)	(30,861)	(32,510)
Total equity		2,439,773	2,334,366	2,418,499

Notes to the financial statements are included on pages 10 to 18.

EBOS GROUP LIMITED
CONDENSED CONSOLIDATED CASH FLOW STATEMENT

For the six months ended 31 December 2024

Notes	Six months 31 Dec 24 A\$'000 (unaudited)	Six months 31 Dec 23 A\$'000 (unaudited)	Year ended 30 Jun 24 A\$'000 (audited)
Cash flows from operating activities			
	6,071,681	6,559,650	13,198,911
Receipts from sale of goods and services			
Interest received	3,552	3,952	7,320
Dividends received from associates	5,721	8,731	11,929
Payments for purchase of goods and services	(5,796,883)	(6,371,675)	(12,665,460)
Taxes paid	(39,248)	(46,477)	(103,523)
Interest paid	(54,982)	(48,718)	(100,941)
Net cash inflow from operating activities	189,841	105,463	348,236
Cash flows from investing activities			
	203	218	418
Sale of property, plant and equipment			
Purchase of property, plant and equipment	(36,277)	(32,042)	(61,559)
Payments for capital work in progress	(19,473)	(32,229)	(34,340)
Payments for intangible assets	(8,553)	(2,333)	(22,939)
Acquisition of subsidiaries	(49,820)	(223,559)	(246,893)
Investment in associates	(602)	-	(2,038)
Investment in other financial assets	(20,075)	(9,314)	(10,771)
Net cash outflow from investing activities	(134,597)	(299,259)	(378,122)
Cash flows from financing activities			
	843	858	1,611
Proceeds from issue of shares			
Proceeds from borrowings	1,250,488	475,319	484,222
Repayment of borrowings	(1,186,043)	-	(226,727)
Repayment of lease liabilities	(29,571)	(28,375)	(68,649)
Dividends paid to equity holders of parent	(70,399)	(101,692)	(156,128)
Net cash (outflow)/inflow from financing activities	(34,682)	346,110	34,329
Net increase in cash held	20,562	152,314	4,443
Effect of exchange rate fluctuations on cash held	483	1,113	554
Net cash and cash equivalents at beginning of period	216,883	211,886	211,886
Net cash and cash equivalents at end of period	237,928	365,313	216,883

Notes to the financial statements are included on pages 10 to 18.

EBOS GROUP LIMITED

NOTES TO THE CONDENSED CONSOLIDATED INTERIM FINANCIAL STATEMENTS

For the six months ended 31 December 2024

1. FINANCIAL STATEMENTS

These unaudited condensed consolidated interim financial statements have been prepared in accordance with New Zealand Generally Accepted Accounting Practice ("NZGAAP") as appropriate for condensed interim financial statements. They comply with the New Zealand Equivalent to International Accounting Standard 34 (NZ IAS 34) *Interim Financial Reporting* and International Accounting Standard IAS 34.

EBOS Group Limited ('the Company') is a profit-oriented company incorporated in New Zealand, registered under the Companies Act 1993 and dual listed on both the New Zealand Stock Exchange and the Australian Securities Exchange.

The Company is a Tier 1 for-profit entity in terms of the New Zealand External Reporting Board Standard A1.

The Company is a FMC reporting entity for the purposes of the Financial Markets Conduct Act 2013, and its financial statements comply with this Act.

These financial statements should be read in conjunction with the financial statements and related notes included in the Group's Annual Report for the year ended 30 June 2024.

The accounting policies and methods of computation are consistent with those of the previous year.

The information is presented in thousands of Australian dollars unless otherwise stated.

2. PROFIT FROM OPERATIONS

	Six months 31 Dec 24 A\$'000 (unaudited)	Six months 31 Dec 23 A\$'000 (unaudited)	Year ended 30 Jun 24 A\$'000 (audited)
(a) Revenue			
Community Pharmacy	3,144,226	3,912,432	7,809,802
Institutional Healthcare	2,157,241	1,965,819	4,004,660
Contract Logistics Services	71,108	72,153	139,604
Contract Logistics Sales	421,301	451,774	866,126
Interdivisional eliminations	(106,681)	(105,872)	(210,182)
Healthcare	5,687,195	6,296,306	12,610,010
Animal Care	304,215	286,182	579,044
	5,991,410	6,582,488	13,189,054

EBOS GROUP LIMITED
NOTES TO THE CONDENSED CONSOLIDATED INTERIM FINANCIAL STATEMENTS (Continued)

For the six months ended 31 December 2024

2. PROFIT FROM OPERATIONS (Continued)

	Six months 31 Dec 24 A\$'000 (unaudited)	Six months 31 Dec 23 A\$'000 (unaudited)	Year ended 30 Jun 24 A\$'000 (audited)
(b) Profit before net finance costs and tax expense			
Profit before net finance costs and tax expense has been arrived at after charging the following expenses by nature:			
One-off items ⁽¹⁾	(15,228)	(10,100)	(18,748)
Cost of sales	(5,191,426)	(5,766,378)	(11,546,832)
Write-down of inventory	(652)	(2,874)	(9,316)
Impairment loss on trade and other receivables	(114)	(493)	(461)
Depreciation of property, plant and equipment	(15,293)	(16,395)	(30,325)
Depreciation on right of use assets	(32,043)	(31,655)	(62,134)
Amortisation of finite life intangibles attributable to fair value adjustment for the LifeHealthcare Group acquisition	(13,090)	(13,090)	(26,181)
Amortisation of other finite life intangibles	(8,136)	(5,203)	(10,231)
Short-term and low value asset leases	(6,814)	(4,261)	(10,333)
Donations	(357)	(166)	(698)
Employee benefit expense	(257,090)	(257,595)	(521,864)
Defined contribution plan expense	(20,402)	(15,999)	(34,708)
Other expenses	(231,296)	(228,089)	(453,437)
	<u>(5,791,941)</u>	<u>(6,352,298)</u>	<u>(12,725,268)</u>

(1) One-off items comprise (i) merger and acquisition costs of \$5.4m (December 2023: \$10.1m, June 2024: \$10.1m) and (ii) non-recurring restructuring and site transition costs of \$9.8m (December 2023: nil, June 2024: \$8.6m).

3. SHARE CAPITAL

	No. '000	Six months 31 Dec 24 A\$'000 (unaudited)	No. '000	Six months 31 Dec 23 A\$'000 (unaudited)	No. '000	Year ended 30 Jun 24 A\$'000 (audited)
Fully paid ordinary shares						
Balance at beginning of period	193,243	1,937,210	191,604	1,889,863	191,604	1,889,863
Dividend reinvested	1,221	38,663	-	-	1,399	45,736
Performance rights	192	-	186	-	186	-
Issue of shares to staff under employee share plan	29	959	27	932	54	1,808
Employee share issue costs	-	(116)	-	(74)	-	(197)
	<u>194,685</u>	<u>1,976,716</u>	<u>191,817</u>	<u>1,890,721</u>	<u>193,243</u>	<u>1,937,210</u>

EBOS GROUP LIMITED
NOTES TO THE CONDENSED CONSOLIDATED INTERIM FINANCIAL STATEMENTS (Continued)

For the six months ended 31 December 2024

4. DIVIDENDS

	AUD Cents per share	Six months 31 Dec 24 A\$'000 (unaudited)	AUD Cents per share	Six months 31 Dec 23 A\$'000 (unaudited)	AUD Cents per share	Year ended 30 Jun 24 A\$'000 (audited)
Recognised amounts						
Fully paid ordinary shares						
Final – prior year	56.1	108,167	52.7	100,879	52.7	100,879
Interim – current year	-	-	-	-	53.7	102,796
	56.1	108,167	52.7	100,879	106.4	203,675
Unrecognised amounts						
Final dividend	-	-	-	-	56.8	109,788
Interim dividend	51.6	100,526	52.9	101,443	-	-
	51.6	100,526	52.9	101,443	56.8	109,788

Dividends are approved by the Board in New Zealand dollars. Dividends recognised in the Statement of Changes in Equity are converted from New Zealand dollars to Australian Dollars at the exchange rate applicable on the date the dividend was approved. Unrecognised dividends are converted at the exchange rate applicable on the reporting date. The Board approved an interim dividend of 57.0 New Zealand cents per share on 18 February 2025. The record date for the dividend is 28 February 2025 and the dividend will be paid on 21 March 2025.

The following table shows dividends approved in New Zealand dollars:

	Six months 31 Dec 24 NZD Cents per share	Six months 31 Dec 23 NZD Cents per share	Year ended 30 Jun 24 NZD Cents per share
Recognised amounts			
Fully paid ordinary shares			
Final – prior year	61.5	57.0	57.0
Interim – current year	-	-	57.0
	61.5	57.0	114.0
Unrecognised amounts			
Final dividend	-	-	61.5
Interim dividend	57.0	57.0	-
	57.0	57.0	61.5

New Zealand dollar dividends paid to equity holders of the parent are translated into Australian dollars and disclosed in the cash flow statement at the foreign currency exchange rate applicable on the date they are paid.

EBOS GROUP LIMITED
NOTES TO THE CONDENSED CONSOLIDATED INTERIM FINANCIAL STATEMENTS (Continued)

For the six months ended 31 December 2024

5. NOTES TO THE CASH FLOW STATEMENT

	Six months 31 Dec 24 A\$'000 (unaudited)	Six months 31 Dec 23 A\$'000 (unaudited)	Year ended 30 Jun 24 A\$'000 (audited)
Reconciliation of profit for the period with cash flows from operating activities			
Profit for the period	111,719	137,256	273,085
Add/(less) non-cash items:			
Depreciation of property, plant and equipment	15,293	16,395	30,325
Depreciation on right of use assets	32,043	31,655	62,134
Amortisation of finite life intangibles attributable to fair value adjustment for the LifeHealthcare Group acquisition	13,090	13,090	26,181
Amortisation of other finite life intangibles	8,136	5,203	10,231
(Gain)/loss on sale of property, plant and equipment	(275)	48	711
Share of profit from associates	(7,807)	(6,534)	(12,938)
Expense recognised in respect of share-based payments	2,410	5,907	11,794
Deferred tax	1,393	183	3,832
	64,283	65,947	132,270
Movements in working capital:			
Trade and other receivables	70,852	(29,560)	2,962
Prepayments	(1,596)	(9,176)	(7,824)
Inventories	(35,996)	(100,041)	23,797
Current tax refundable/payable	4,368	10,252	1,177
Trade and other payables	11,459	30,797	(80,300)
Employee benefits	(15,235)	(10,886)	1,976
Foreign currency translation of working capital balances	6,880	(1,156)	(2,445)
	40,732	(109,770)	(60,657)
Balances classified as investing activities	(30,240)	11,859	2,148
Working capital items acquired (including fair value adjustments)	3,347	171	1,390
Net cash inflow from operating activities	189,841	105,463	348,236

EBOS GROUP LIMITED
NOTES TO THE CONDENSED CONSOLIDATED INTERIM FINANCIAL STATEMENTS (Continued)

For the six months ended 31 December 2024

6. SEGMENT INFORMATION
(a) Products and services from which reportable segments derive their revenues

 The Group's reportable segments under NZ IFRS 8 *Operating Segments* are as follows:

Healthcare: Incorporates the sale of healthcare products in a range of sectors, including distribution of medical devices and medical consumables, own brands, retail healthcare, pharmacy and logistic services and wholesale activities.

Animal Care: Incorporates the sale of animal care products in a range of sectors, own brands, retail and wholesale activities.

Corporate: Includes net funding costs and central administration expenses that have not been allocated to the Healthcare or Animal Care segments.

(b) Segment revenues and results

The following is an analysis of the Group's revenue and results by reportable segment:

	Healthcare A\$'000	Animal Care A\$'000	Corporate A\$'000	Group A\$'000
Six months ended 31 December 2024 (unaudited):				
Revenue from external customers	5,687,195	304,215	-	5,991,410
EBITDA	235,239	59,344	(18,745)	275,838
Depreciation of property, plant and equipment	(13,155)	(2,138)	-	(15,293)
Depreciation on right of use assets	(28,116)	(3,469)	(458)	(32,043)
Amortisation of finite life intangibles attributable to fair value adjustment for the LifeHealthcare Group acquisition	(13,090)	-	-	(13,090)
Amortisation of other finite life intangibles	(7,689)	(447)	-	(8,136)
EBIT	173,189	53,290	(19,203)	207,276
Net finance costs	-	-	(51,430)	(51,430)
Tax (expense)/benefit	(47,890)	(14,624)	18,387	(44,127)
Profit for the period	125,299	38,666	(52,246)	111,719
Non-controlling interests	(1,230)	-	-	(1,230)
Profit for the period attributable to owners of the Company	124,069	38,666	(52,246)	110,489
Six months ended 31 December 2023 (unaudited):				
Revenue from external customers	6,296,306	286,182	-	6,582,488
EBITDA	273,568	47,162	(17,663)	303,067
Depreciation of property, plant and equipment	(14,483)	(1,912)	-	(16,395)
Depreciation on right of use assets	(27,941)	(3,164)	(550)	(31,655)
Amortisation of finite life intangibles attributable to fair value adjustment for the LifeHealthcare Group acquisition	(13,090)	-	-	(13,090)
Amortisation of other finite life intangibles	(4,874)	(329)	-	(5,203)
EBIT	213,180	41,757	(18,213)	236,724
Net finance costs	-	-	(44,766)	(44,766)
Tax (expense)/benefit	(59,614)	(10,836)	15,748	(54,702)
Profit for the period	153,566	30,921	(47,231)	137,256
Non-controlling interests	(1,081)	-	-	(1,081)
Profit for the period attributable to owners of the Company	152,485	30,921	(47,231)	136,175

EBOS GROUP LIMITED
NOTES TO THE CONDENSED CONSOLIDATED INTERIM FINANCIAL STATEMENTS (Continued)

For the six months ended 31 December 2024

6. SEGMENT INFORMATION (Continued)

	Healthcare A\$'000	Animal Care A\$'000	Corporate A\$'000	Group A\$'000
Year ended 30 June 2024 (audited):				
Revenue from external customers	12,610,010	579,044	-	13,189,054
EBITDA	537,485	103,987	(35,877)	605,595
Depreciation of property, plant and equipment	(26,193)	(4,132)	-	(30,325)
Depreciation on right of use assets	(55,102)	(5,978)	(1,054)	(62,134)
Amortisation of finite life intangibles attributable to fair value adjustment for the LifeHealthcare Group acquisition	(26,181)	-	-	(26,181)
Amortisation of other finite life intangibles	(9,578)	(653)	-	(10,231)
EBIT	420,431	93,224	(36,931)	476,724
Net finance costs	-	-	(93,621)	(93,621)
Tax (expense)/benefit	(118,264)	(24,448)	32,694	(110,018)
Profit for the period	302,167	68,776	(97,858)	273,085
Non-controlling interests	(1,536)	-	-	(1,536)
Profit for the period attributable to owners of the Company	300,631	68,776	(97,858)	271,549

The accounting policies of the reportable segments are consistent with the Group's accounting policies. Segment result represents profit before depreciation, amortisation, net finance costs and tax. This is the measure reported to the chief operating decision maker for the purposes of resource allocation and assessment of segment performance.

(c) Segment assets

Assets are not allocated to operating segments as they are not reported to the chief operating decision-maker at segment level.

(d) Revenues from major products and services

The Group's major products and services are transacted the same as its reportable segments i.e. Healthcare, Animal Care and Corporate.

(e) Geographical information

The Group operates in two principal geographical areas: (1) Australia and (2) New Zealand (country of domicile) and Southeast Asia.

The Group's revenue from external customers by geographical location (of the reportable segment) and information about its segment assets (non-current assets excluding investments in associates and deferred tax assets) are detailed below:

	Six months 31 Dec 24 A\$'000 (unaudited)	Six months 31 Dec 23 A\$'000 (unaudited)	Year ended 30 Jun 24 A\$'000 (audited)
Revenue from external customers			
Australia	4,649,117	5,279,075	10,647,831
New Zealand and Southeast Asia	1,342,293	1,303,413	2,541,223
	5,991,410	6,582,488	13,189,054
Non-current assets			
Australia	2,906,101	2,753,619	2,843,070
New Zealand and Southeast Asia	673,246	618,351	623,433
	3,579,347	3,371,970	3,466,503

EBOS GROUP LIMITED

NOTES TO THE CONDENSED CONSOLIDATED INTERIM FINANCIAL STATEMENTS (Continued)

For the six months ended 31 December 2024

7. BANK FACILITY AND BORROWINGS

The Group fully complies with and operates within the financial covenants under the arrangements with its bankers. During the period, the Group entered into agreements to refinance its term debt facilities, total of \$1,600.0m and NZ\$150.0m, due to mature between two to five years. At 31 December 2024 the Group had unutilised term loan facilities of \$505.4m (December 2023: \$251.0m, June 2024: \$577.4m).

The Group also has a secured trade debtor securitisation facility of which \$390.3m was unutilised at 31 December 2024 (December 2023: \$228.3m, June 2024: \$219.3m). In August 2024, the Group entered into an agreement to extend the maturity date of this securitisation facility to September 2026. In addition, the Group has a \$5.0m term debt facility secured by property, plant and equipment (December 2023: \$75.0m, June 2024: \$75.0m). All other debt is linked to a corporate guarantee structure established under bank financing arrangements.

As at 31 December 2024, the maturity profile of the Group's term debt and securitisation facilities was:

<u>Facility</u>	<u>Amount</u>	<u>Undrawn</u>	<u>Maturity</u>
Term debt facilities	\$ 57.5m	\$ 19.5m	< 1 year
Term debt facilities	\$305.0m	-	1-2 years
Term debt facilities	\$135.9m	\$135.9m	2-3 years
Term debt facilities	\$750.0m	-	3-4 years
Term debt facilities	\$550.0m	\$350.0m	> 5 years
Securitisation facility	\$400.0m	\$390.3m	1-2 years

8. FINANCIAL INSTRUMENTS

The Group enters into forward foreign currency exchange contracts to hedge trading transactions, including anticipated transactions, denominated in foreign currencies; and uses interest rate swaps and interest rate collars to manage cash flow interest rate risk.

Derivatives are initially recognised at fair value on the date a derivative contract is entered into and are subsequently remeasured to their fair value. The resulting gain or loss is recognised in profit or loss immediately unless the derivative is designated and effective as a hedging instrument, in which event the timing of the recognition in profit or loss depends on the nature of the hedge relationship. The Group designates certain derivatives as cash flow hedges of highly probable forecast transactions.

	Six months 31 Dec 24 A\$'000 (unaudited)	Six months 31 Dec 23 A\$'000 (unaudited)	Year ended 30 Jun 24 A\$'000 (audited)
Fair value of derivative financial instruments			
Other financial assets – derivatives (at fair value)			
Forward foreign exchange contracts	3,815	76	213
Interest rate collars	2,109	4,625	6,514
	<u>5,924</u>	<u>4,701</u>	<u>6,727</u>
Other financial liabilities – derivatives (at fair value)			
Forward foreign exchange contracts	449	493	617
Other financial liabilities – consideration for remaining non-controlling interests (Note 9)	46,000	33,000	35,000
	<u>46,449</u>	<u>33,493</u>	<u>35,617</u>

The Group has categorised these derivatives, both financial assets and financial liabilities, as Level 2 under the fair value hierarchy contained within NZ IFRS 13 *Fair Value Measurement*.

The fair value of foreign currency forward exchange contracts is determined using a discounted cash flow valuation. Key inputs include observable forward exchange rates, at the measurement date, with the resulting value discounted back to present values. Interest rate swaps and interest rate collars are valued using a discounted cash flow valuation. Key inputs for the valuation of interest rate swaps and interest rate collars are the estimated future cash flows based on observable yield curves at the end of the reporting period, discounted at a rate that reflects the credit risk of the various counterparties.

There have been no changes in valuation techniques used for either forward foreign currency exchange contracts, interest rate swaps, interest rate collars, or other financial liabilities during the current reporting period.

EBOS GROUP LIMITED**NOTES TO THE CONDENSED CONSOLIDATED INTERIM FINANCIAL STATEMENTS (Continued)**

For the six months ended 31 December 2024

9. ACQUISITION INFORMATION

On 4 November 2024, the Group completed the acquisition of the business operations of Pacific Surgical Inc., a specialist orthopaedic device distributor in the Philippines, for total consideration of \$47.0m.

Other than the above, there are no material acquisitions during the period. Due to the proximity of the acquisition date to the balance date, the purchase price allocation for acquisitions during the period is measured on a provisional basis and is subject to change pending the finalisation of the valuation of the assets acquired and liabilities assumed. Combined details of acquisitions undertaken during the current period are as follows:

	Carrying value A\$'000 (unaudited)	Fair value adjustment A\$'000 (unaudited)	Fair value on acquisition A\$'000 (unaudited)
Current assets			
Cash and cash equivalents	1,225	-	1,225
Trade and other receivables	10,397	(4,890) ¹	5,507
Prepayments	302	(302) ²	-
Inventories	6,994	(2,047) ³	4,947
Non-current assets			
Property, plant and equipment	3,530	(1,348) ⁴	2,182
Right of use assets	-	222 ⁵	222
Deferred tax assets	-	2,401 ⁶	2,401
Current liabilities			
Trade and other payables	(5,613)	(504) ⁷	(6,117)
Current tax payable	(43)	(108) ⁶	(151)
Lease liabilities	-	(119) ⁵	(119)
Employee benefits	(201)	(265) ⁸	(466)
Non-current liabilities			
Trade and other payables	-	(428) ⁷	(428)
Lease liabilities	-	(103) ⁵	(103)
Deferred tax liabilities	(26)	-	(26)
Employee benefits	(96)	-	(96)
Net assets acquired	16,469	(7,491)	8,978
Goodwill on acquisition			59,428
Total consideration			68,406
Less cash and cash equivalents acquired			(1,225)
Less deferred purchase consideration			(20,855)
Add deferred purchase consideration paid in relation to prior year acquisitions			3,494
Net cash outflow from acquisition			49,820

1. To recognise the fair value of trade and other receivables on acquisition.
2. To recognise the fair value of prepayments on acquisition.
3. To recognise the fair value of inventories on acquisition.
4. To recognise the fair value of property, plant and equipment on acquisition.
5. To recognise the fair value of right of use assets and related lease liabilities on acquisition.
6. To recognise current and deferred tax balances on acquisition.
7. To recognise the fair value of trade and other payables on acquisition.
8. To recognise the fair value of employee benefits on acquisition.

For the six months ended 31 December 2024

9. ACQUISITION INFORMATION (Continued)**LifeHealthcare Group acquisition – Put option over non-controlling interests**

On 31 May 2022, the Group, through its subsidiary EBOS Medical Devices Pty Ltd, acquired 100% of the equity interest in Pacific Health Supplies TopCo1 Pty Ltd and Pacific Health Supplies TopCo2 Pty Ltd (LifeHealthcare Group), including 51% interest in Transmedic Pte Ltd (Transmedic, a subsidiary of LifeHealthcare Group). The Group also entered into arrangements providing a pathway to 100% ownership of Transmedic, resulting in a financial liability – derivative of \$137.0m initially recognised on the balance sheet as at 30 June 2022 and a corresponding adjustment to non-controlling interests. Subsequently, the amount expected to be paid at the time of exercise of the option was reassessed to \$165.0m, as at 30 June 2023, with the movement of \$28.0m recognised directly in equity.

In the prior year, the Group purchased an additional 39% shareholding in Transmedic for a consideration of \$134.6m (SG\$118.7m), to increase its shareholding in Transmedic to 90%. An option arrangement was also agreed to facilitate the Group moving to 100% ownership. As at 31 December 2024, the financial liability – derivative was \$46.0m (December 2023: \$33.0m, June 2024: \$35.0m). Subsequent changes to the carrying value of the financial liability – derivative are recognised directly in equity within non-controlling interests.

10. EVENTS AFTER BALANCE DATE

Subsequent to 31 December 2024, the Board approved an interim dividend to shareholders. For further details please refer to Note 4.

In January 2025, the Group increased its equity interest in Transmedic to 100%.

EBOS GROUP LIMITED

DIRECTORY

CORPORATE HEAD OFFICE

108 Wrights Road
PO Box 411
Christchurch 8024
New Zealand
Telephone +64 3 338 0999
E-mail: ebos@ebos.co.nz

AUSTRALIA HEAD OFFICE

Level 7, 737 Bourke Street
Docklands 3008
Melbourne
Australia
Telephone +61 3 9918 5555
Email: ebos@ebosgroup.com

WEBSITE ADDRESS

www.ebosgroup.com

DIRECTORS

Elizabeth Coutts	Independent Chair
Tracey Batten	Independent Director
Mark Bloom	Independent Director
Coline McConville	Independent Director (appointed February 2025)
Stuart McLauchlan	Independent Director
Matt Muscio	Non-executive Director (appointed January 2025)
Julie Tay	Independent Director

SHARE REGISTER

Computershare Investor Services Ltd
Private Bag 92119
Auckland 1142
New Zealand
Telephone: +64 9 488 8777

Computershare Investor Services Pty Ltd
GPO Box 3329
Melbourne, Victoria 3001
Australia
Telephone: 1800 501 366

Managing Your Shareholding Online:

To change your address, update your payment instructions and to view your investment portfolio including transactions, please visit:
www.computershare.com/investorcentre

General enquiries can be directed to:

- enquiry@computershare.co.nz
- Private Bag 92119, Auckland 1142, New Zealand or GPO Box 3329, Melbourne, Victoria 3001, Australia
- Telephone (NZ) +64 9 488 8777 or (Aust) 1800 501 366
- Facsimile (NZ) +64 9 488 8787 or (Aust) +61 3 9473 2500

Please assist our registrar by quoting your CSN or shareholder number.